Source: Annual Congress 2002 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Pérez, G. Juliá, M. Ponce, E. Gorriz, J. M. Pulido, P. Cabrera (Las Palmas de Gran Canaria, Spain). Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension. Eur Respir J 2002; 20: Suppl. 38, 2308

Member's Comments

No comment yet.

Related content which might interest you: Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016 Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Nitric oxide metabolite flux during exercise in pulmonary arterial hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 Infused nitric oxide in experimental pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 348s Year: 2007 Upregulation of endothelial nitric oxide synthase in pulmonary artery of infants with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 694s Year: 2004 Physical training and metabolics of nitric oxide in individuals with idiopathic pulmonary arterial hypertension. Source: International Congress 2019 – Exercise tolerance and its determinants across pathologies Year: 2019 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Haemodynamic testing in primary pulmonary hypertension - effects of nitric oxide, iloprost and oxygen Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001 Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Source: Eur Respir J 2002; 20: 52-58 Year: 2002 Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012 Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013